These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20156056)

  • 1. Challenges in reintroducing tuberculosis medications after hepatotoxicity.
    Saukkonen J
    Clin Infect Dis; 2010 Mar; 50(6):840-2. PubMed ID: 20156056
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens.
    Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatic function and antitubercular drugs].
    Fossati C
    Clin Ter; 1978 Sep; 86(5):495-501. PubMed ID: 367684
    [No Abstract]   [Full Text] [Related]  

  • 5. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hepatic drug monitoring in patients exposed to antitubercular treatment].
    Domínguez JP; Amenábar E; Mendoza F; Pivet H; Palacios L; Lagos A; Diaz N; Calderón J; Cardenas R; Pérez-Olea J
    Rev Med Chil; 1982 Aug; 110(8):733-7. PubMed ID: 7156604
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?
    Walker NF; Kliner M; Turner D; Bhagani S; Cropley I; Hopkins S; Lipman M
    Thorax; 2009 Oct; 64(10):918. PubMed ID: 19786720
    [No Abstract]   [Full Text] [Related]  

  • 9. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Am J Respir Crit Care Med; 2007 Apr; 175(8):858; author reply 858-9. PubMed ID: 17405943
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of anti-tuberculosis drug-induced hepatotoxicity.
    Tahaoğlu K; Ataç G; Sevim T; Tärün T; Yazicioğlu O; Horzum G; Gemci I; Ongel A; Kapakli N; Aksoy E
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):65-9. PubMed ID: 11263519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Surveillance and complications of antituberculosis chemotherapy].
    Duroux P
    Rev Prat; 1979 Jun; 29(33):2681-90. PubMed ID: 225779
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.
    Araújo-Mariz C; Lopes EP; Acioli-Santos B; Maruza M; Montarroyos UR; Ximenes RA; Lacerda HR; Miranda-Filho Dde B; Albuquerque Mde F
    PLoS One; 2016; 11(6):e0157725. PubMed ID: 27332812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tuberculosis treatment in adults].
    Gatey C; Bouvet E
    Rev Prat; 2012 Apr; 62(4):495-501. PubMed ID: 22641888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liver and antitubercular drug therapy].
    Viroglio AL; Piñeyro JO; Acosta A; Munaro N; Escarguel Malbrán J; Pérez JA
    Rev Fac Cienc Med Cordoba; 1974; 32(1):19-36. PubMed ID: 4458009
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antitubercular drug-induced liver injuries].
    Guo Y; Cui D
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Sharma et Al and Saukkonen et Al.
    Heller T; Wallrauch C; Lessells RJ
    Clin Infect Dis; 2010 Jul; 51(2):255. PubMed ID: 20560741
    [No Abstract]   [Full Text] [Related]  

  • 17. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications.
    Chang JC; Liu EH; Lee CN; Lin YC; Yu MC; Bai KJ; Chen HY
    Int J Tuberc Lung Dis; 2012; 16(3):376-8. PubMed ID: 22230213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tuberculostatic agents].
    Dijkman JH
    Ned Tijdschr Geneeskd; 1987 Oct; 131(42):1845-9. PubMed ID: 3670495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.